These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 33209988)

  • 1. Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.
    Martínez-Del Río J; Piqueras-Flores J; Nieto-Sandoval Martín de la Sierra P; Negreira-Caamaño M; Águila-Gordo D; Mateo-Gómez C; Salas-Bravo D; Rodríguez-Martínez M
    Med Clin (Engl Ed); 2020 Dec; 155(11):473-481. PubMed ID: 33209988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection.
    Martínez-Del Río J; Piqueras-Flores J; Nieto-Sandoval Martín de la Sierra P; Negreira-Caamaño M; Águila-Gordo D; Mateo-Gómez C; Salas-Bravo D; Rodríguez-Martínez M
    Med Clin (Barc); 2020 Dec; 155(11):473-481. PubMed ID: 32782110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19.
    Roy-Vallejo E; Sánchez Purificación A; Torres Peña JD; Sánchez Moreno B; Arnalich F; García Blanco MJ; López Miranda J; Romero-Cabrera JL; Herrero Gil CR; Bascunana J; Rubio-Rivas M; Pintos Otero S; Martínez Sempere V; Ballano Rodríguez-Solís J; Gil Sánchez R; Luque Del Pino J; González Noya A; Navas-Alcántara MS; Cortés Rodríguez B; Alcalá JN; Suárez-Lombraña A; Andrés Soler J; Gómez-Huelgas R; Casas-Rojo JM; Millán Núñez-Cortés J; On Behalf Of The Semi-Covid-Network
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34204014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
    Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
    BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Differences among renin-angiotensin system inhibitor drugs in prognosis of hypertense patients with COVID-19].
    Negreira-Caamaño M; Martínez-Del-Río J; Nieto-Sandoval-Martín-de-la-Sierra P; Águila-Gordo D; Mateo-Gómez C; Rodríguez-Martínez M; Salas-Bravo D; Piqueras-Flores J
    Arch Cardiol Mex; 2022 Apr; 93(Supl 6):58-65. PubMed ID: 35389602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients.
    Genet B; Vidal JS; Cohen A; Boully C; Beunardeau M; Marine Harlé L; Gonçalves A; Boudali Y; Hernandorena I; Bailly H; Lenoir H; Piccoli M; Chahwakilian A; Kermanach L; de Jong L; Duron E; Girerd X; Hanon O
    J Am Med Dir Assoc; 2020 Nov; 21(11):1539-1545. PubMed ID: 33138935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study.
    Zhong Y; Zhao L; Wu G; Hu C; Wu C; Xu M; Dong H; Zhang Q; Wang G; Yu B; Lv J; Wu C; Zhang S; Cao C; Shu L; Pan Y; Liu X; Wu F
    J Int Med Res; 2020 Dec; 48(12):300060520979151. PubMed ID: 33322988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.
    Chen C; Wang F; Chen P; Jiang J; Cui G; Zhou N; Moroni F; Moslehi JJ; Ammirati E; Wang DW
    J Am Heart Assoc; 2020 Nov; 9(21):e017736. PubMed ID: 32807002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
    J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
    Pranata R; Permana H; Huang I; Lim MA; Soetedjo NNM; Supriyadi R; Soeroto AY; Alkatiri AA; Firman D; Lukito AA
    Diabetes Metab Syndr; 2020; 14(5):983-990. PubMed ID: 32615377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies.
    COVID-19 RISk and Treatments (CORIST) Collaboration
    Vascul Pharmacol; 2020 Dec; 135():106805. PubMed ID: 32992048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.
    Wang Y; Chen B; Li Y; Zhang L; Wang Y; Yang S; Xiao X; Qin Q
    J Med Virol; 2021 Mar; 93(3):1370-1377. PubMed ID: 33095513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARB) Are Protective Against ICU Admission and Mortality for Patients With COVID-19 Disease.
    ElAbd R; AlTarrah D; AlYouha S; Bastaki H; Almazeedi S; Al-Haddad M; Jamal M; AlSabah S
    Front Med (Lausanne); 2021; 8():600385. PubMed ID: 33748156
    [No Abstract]   [Full Text] [Related]  

  • 18. Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19.
    Kang SH; Lee DH; Han KD; Jung JH; Park SH; Dai AM; Wei HG; Yoon CH; Youn TJ; Chae IH; Kim CH
    Clin Hypertens; 2021 Jun; 27(1):11. PubMed ID: 34059140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial.
    Bauer A; Schreinlechner M; Sappler N; Dolejsi T; Tilg H; Aulinger BA; Weiss G; Bellmann-Weiler R; Adolf C; Wolf D; Pirklbauer M; Graziadei I; Gänzer H; von Bary C; May AE; Wöll E; von Scheidt W; Rassaf T; Duerschmied D; Brenner C; Kääb S; Metzler B; Joannidis M; Kain HU; Kaiser N; Schwinger R; Witzenbichler B; Alber H; Straube F; Hartmann N; Achenbach S; von Bergwelt-Baildon M; von Stülpnagel L; Schoenherr S; Forer L; Embacher-Aichhorn S; Mansmann U; Rizas KD; Massberg S;
    Lancet Respir Med; 2021 Aug; 9(8):863-872. PubMed ID: 34126053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
    Cohen JB; Hanff TC; William P; Sweitzer N; Rosado-Santander NR; Medina C; Rodriguez-Mori JE; Renna N; Chang TI; Corrales-Medina V; Andrade-Villanueva JF; Barbagelata A; Cristodulo-Cortez R; Díaz-Cucho OA; Spaak J; Alfonso CE; Valdivia-Vega R; Villavicencio-Carranza M; Ayala-García RJ; Castro-Callirgos CA; González-Hernández LA; Bernales-Salas EF; Coacalla-Guerra JC; Salinas-Herrera CD; Nicolosi L; Basconcel M; Byrd JB; Sharkoski T; Bendezú-Huasasquiche LE; Chittams J; Edmonston DL; Vasquez CR; Chirinos JA
    Lancet Respir Med; 2021 Mar; 9(3):275-284. PubMed ID: 33422263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.